Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335937 | 1.00 | CA1 (0.36) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL7290030 | 0.97 | CA1 (0.32) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL3056761 | 0.92 | — | — | |
| SCHEMBL3128017 | 0.75 | PHGDH (0.50) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL5363728 | 0.75 | TDP1 (0.46) | CA1CA2POLBKMT2AMEN1 | |
| SCHEMBL6333240 | 0.75 | KDM4E (0.37) | TSHRALDH1A1KDM4EUSP2CYP3A4 | |
| SCHEMBL6342657 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL7024977 | 0.74 | CA1 (0.36) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL176589 | 0.74 | CA2 (0.36) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL1646187 | 0.74 | CA1 (0.48) | CA1CA2POLBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5126455-A | Preparation of substituted alkali metal piperidine-4-carboxylates | GLAXO INC. (US) | 1992-06-30 | — | — | US | claimed |
| US-5039804-A | Hydrolysis of 1,3,8,-triazaspiro 4.5!decane-2,4-diones, chemical intermediates for opium type analgesics | GLAXO INC. (US) | 1991-08-13 | — | — | US | claimed |
| EP-0433048-A1 | Preparation of substituted alkali metal piperidine-4-carboxylates | GLAXO WELLCOME INC. (US) | 1991-06-19 | — | — | EP | claimed |
| EP-1575493-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC SULFONYLUREIDO PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
| EP-1575493-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC SULFONYLUREIDO PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1778654-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | Crystalgenomics, Inc. (KR) | 2007-05-02 | — | — | EP | disclosed |
| US-7202258-B2 | α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7037941-B2 | Alpha-and Beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2006006832-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | CRYSTALGENOMICS, INC. (KR) | 2006-01-19 | — | — | WO | disclosed |
| US-20050267214-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-01 | — | — | US | disclosed |
| EP-0666842-A1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0666841-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0666843-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994010136-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994010134-A1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994010133-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-5126455-A | Preparation of substituted alkali metal piperidine-4-carboxylates | GLAXO INC. (US) | 1992-06-30 | — | — | US | disclosed |
| US-5039804-A | Hydrolysis of 1,3,8,-triazaspiro 4.5!decane-2,4-diones, chemical intermediates for opium type analgesics | GLAXO INC. (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0433048-A1 | Preparation of substituted alkali metal piperidine-4-carboxylates | GLAXO WELLCOME INC. (US) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267214-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | ASPH, DNPEP, PEPD | CA1 408/4885CA2 2526/4885POLB 528/4885 |
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | CA1 3138/4885CA2 1013/4885POLB 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.